• SENSEX
    NIFTY 50
Business

Interview: Biocon CMD Kiran Mazumdar Shaw on biosimilar business, fund-raising and True North deal

Updated : January 08, 2020 08:08 AM IST

Biocon has to be viewed as a balanced portfolio with small molecules, biologics and research services, says Shaw.
Capex needs of biologics business are high both in terms of manufacturing capacity and R&D investment.
Interview: Biocon CMD Kiran Mazumdar Shaw on biosimilar business, fund-raising and True North deal

You May Also Like

Live TV
Advertisement